Vaxxinity, Inc. (VAXX)

0.0921 +0.0021 (+2.33%) At close: 01:30PM EDT

Vaxxinity, Inc.

505 Odyssey Way
Merritt Island, FL 32953
United States
(254)244-5739
https://www.vaxxinity.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 57

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Louis Garfield Reese IV	Co-Founder & Executive Chairman of the Board	275.57k	N/A	1982
Ms. Mei Mei Hu J.D.	Co-Founder, President, CEO & Director	345.14k	N/A	1983
Ms. Sumita Ray J.D.	Chief Legal, Compliance & Administrative Officer and Corporate Secretary	465.56k	N/A	1974
Mr. Jason Pesile CPA, M.B.A.	Chief Accounting Officer	N/A	N/A	1973
Dr. Jean-Cosme Dodart Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Mark Joinnides MSE	Chief of Staff	N/A	N/A	N/A
Ms. Amy B. Fix M.B.A., M.S., R.A.C.	Head of Regulatory	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Corporate governance

Vaxxinity, Inc.’s ISS governance QualityScore as of 1 June 2024 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 10; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.